Evaluation of the Efficacy of Solifenacin for Preventing Catheter-Related Bladder Discomfort After Transurethral Resection of Bladder Tumors in Patients With Non-Muscle Invasive Bladder Cancer: A Prospective, Randomized, Multicenter Study

Catheter-related bladder discomfort (CRBD) secondary to an indwelling urinary catheter is worse after transurethral resection of a bladder tumor (TUR-BT). We evaluated the incidence of CRBD and the efficacy of solifenacin for preventing CRBD after TUR-BT in patients with non-muscle invasive bladder cancer.

In the present prospective, randomized, multicenter trial, we enrolled 148 patients with non-muscle invasive bladder cancer who underwent elective TUR-BT under general anesthesia. The patients were randomized to group S (n = 72) or group C (n = 76). The primary outcome was evaluable for 134 patients, who were included in the final analysis. Group S received solifenacin (5 mg orally) on the day before, the day, and the day after TUR-BT. The control group (group C) received standard care. CRBD was assessed at 1 and 2 hours postoperatively. Pain was assessed for 3 days starting 6 hours after TUR-BT using the visual analog scale.

The incidence rates of CRBD in groups C and S were 72.2% and 64.5% at 1 hour and 68.1% and 53.2% at 2 hours, respectively. The incidence rates and severity of CRBD at 1 and 2 hours were not different between the 2 groups (P > .05 for both). The visual analog scale scores and the postoperative consumption of analgesics were not different between the 2 groups (P > .05 for both). None of the patients who received solifenacin experienced an adverse event.

Pretreatment with solifenacin (5 mg) failed to decrease the incidence and severity of CRBD after TUR-BT.

Clinical genitourinary cancer. 2016 May 30 [Epub ahead of print]

Jae Min Chung, Hong Koo Ha, Dae Hyun Kim, Jungnam Joo, Sohee Kim, Dong Wan Sohn, Sung Han Kim, Ho Kyung Seo

Department of Urology, Pusan National University Yangsan Hospital, Yangsan, Korea., Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea., Department of Anesthesiology and Pain Medicine, National Cancer Center, Goyang, Gyeonggi, Korea., Biometric Research Branch, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Korea., Biometric Research Branch, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Korea., Department of Urology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Center for Prostate Cancer, National Cancer Center, Goyang, Gyeonggi, Korea., Center for Prostate Cancer, National Cancer Center, Goyang, Gyeonggi, Korea. Electronic address: .